Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Therapy for Post-Transplant Lymphoproliferation
NCT00002657Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- May 1995
- Primary completion
- Nov 2003
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by SWOG Cancer Research Network. Primary endpoint: Complete Remission Rate. Started May 1995; status: completed.
02
Drugs
interferon alfa
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT00002657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002657.